Cingulate (CINGW) Income from Non-Controlling Interests (2022 - 2026)
Cingulate's (CINGW) quarterly Income from Non-Controlling Interests came in at $1.0 in Q2 2026, up 100.12% on a YoY basis from $0.5 in Q2 2025, and up 100.0% quarter-over-quarter from -$518229.0 in Q4 2025.
Powered by 
Analysis
Cingulate (CINGW) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Income from Non-Controlling Interests for 5 consecutive years, with $1.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Non-Controlling Interests rose 100.12% year-over-year to $1.0; the trailing twelve-month figure through Jun 2026 stood at -$2719.0 (up 69.02% YoY), and the FY2025 full-year result was -$1863.0, up 95.01% from the prior year.
- Income from Non-Controlling Interests climbed to $1.0 in Q2 2026 per CINGW's latest filing, from -$518229.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $516366.0 in Q3 2025 and bottomed at -$518229.0 in Q4 2025.
- Historically, Income from Non-Controlling Interests has averaged -$9293.9 across 5 years, with a median of -$8599.0 in 2022.
- The widest YoY moves for Income from Non-Controlling Interests: up 949.14% in 2025, down 811.08% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at $74679.0 in 2022, then sank by 68.68% to $23387.0 in 2023, then slumped by 343.22% to -$56881.0 in 2024, then slumped by 811.08% to -$518229.0 in 2025, then surged by 100.0% to $1.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $1.0, -$518229.0, and $516366.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.84 Bn | 623.08 Bn | 17.26 Bn | - |
| 2 | AbbVie | 441.33 Bn | 434.76 Bn | 12.70 Bn | 3.00 Mn |
| 3 | Merck | 364.84 Bn | 357.70 Bn | 12.21 Bn | -2.00 Mn |
| 4 | Novartis Ag | 266.34 Bn | 258.65 Bn | 11.24 Bn | -7.00 Mn |
| 5 | Pfizer | 159.07 Bn | 147.37 Bn | 10.94 Bn | 10.00 Mn |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | 39.52 Mn |
| 7 | Revolution Medicines | 44.22 Bn | 44.22 Bn | - | - |
| 8 | Incyte | 25.24 Bn | 20.70 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.42 Bn | 18.76 Bn | 683.80 Mn | - |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 1.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.00 |
| Dec 31, 2025 | -518,229.00 |
| Sep 30, 2025 | 516,366.00 |
| Jun 30, 2025 | -857.00 |
| Mar 31, 2025 | -257.00 |
| Dec 31, 2024 | -56,881.00 |
| Sep 30, 2024 | 49,218.00 |
| Jun 30, 2024 | 1,269.00 |
| Mar 31, 2024 | -30,917.00 |
| Dec 31, 2023 | 23,387.00 |
| Sep 30, 2023 | -17,469.00 |
| Jun 30, 2023 | -35,864.00 |
| Mar 31, 2023 | -32,009.00 |
| Dec 31, 2022 | 74,679.00 |
| Sep 30, 2022 | -67,623.00 |
| Jun 30, 2022 | -8,599.00 |
| Mar 31, 2022 | -54,212.00 |